Report Publication Announcement • Mar 3, 2016
Report Publication Announcement
Open in ViewerOpens in native device viewer
Breda, the Netherlands / Ghent, Belgium, 3 March 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will host a conference call and audio webcast on Friday, 11 March 2016 at 3:00 pm CET (9:00 am ET) to discuss the 2015 financial results, as well as provide a fourth quarter business update.
To participate in the conference call, please select your phone number below, and use the confirmation code 61559035. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.
A replay of the webcast will also be available at the argenx website.
argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey. argenx is listed on the Euronext Brussels exchange under the symbol ARGX. www.argenx.com
UK 0800 694 0257
UK Standard International +44 (0) 1452 555 566
UK 0844 493 3800 UK National Call 0871 700 0345
| Australia | 0290 371 687 |
|---|---|
| Austria | 0192 865 68 |
| Belgium | 0817 000 61 |
|---|---|
| Croatia | 0177 766 11 |
| Czech Republic | 2288 804 60 |
| Denmark | 3272 7625 |
| Finland | 0923 195 187 |
| France | 0176 742 428 |
| Germany | 0692 222 3479 |
| Germany | 0692 222 4918 |
| Hungary | 0618 088 303 |
| India | 0223 098 5304 |
| Ireland | 0143 196 48 |
| Ireland | 0150 601 53 |
| Italy | 0236 008 146 |
| Latvia | 6778 2516 |
| Luxembourg | 2088 0695 |
| Netherlands | 0207 176 886 |
| New Zealand | 0992 917 07 |
| Norway | 2156 3013 |
| Poland | 2230 701 18 |
| Romania | 0318 144 957 |
| Russia | 4996 771 036 |
| Slovenia | 0160 093 64 |
| South Africa | 2110 032 02 |
| Spain | 9141 436 69 |
| Sweden | 0850 336 434 |
| Switzerland | 0565 800 007 |
| USA | 1631 510 7498 |
| Argentina | 0800 666 3294 |
|---|---|
| Australia | 1800 020 199 |
| Austria | 0800 005 311 |
| Belgium | 0800 408 64 |
| Brazil | 0800 891 4606 |
| Bulgaria | 0080 011 002 42 |
| Canada | 1866 966 0399 |
|---|---|
| Chile | 1230 020 7879 |
| Columbia | 0180 051 806 20 |
| Cyprus | 8009 5227 |
| Czech Republic | 8001 429 02 |
| Denmark | 8088 8464 |
| Egypt | 0800 000 0318 |
| Estonia | 8000 100 167 |
| Finland | 0800 112 363 |
| France | 0805 632 056 |
| Germany | 0800 101 4960 |
| Greece | 0080 012 6060 |
| Hong Kong | 8009 687 77 |
| Hungary | 0680 016 203 |
| Iceland | 8009 794 |
| India | 0008 001 006 741 |
| Indonesia | 1803 044 113 24 |
| Ireland | 1800 932 187 |
| Israel | 1809 216 057 |
| Italy | 8009 874 96 |
| Japan | 0066 331 324 75 |
| Latvia | 8000 3337 |
| Luxembourg | 8002 7512 |
| Malaysia | 1800 814 521 |
| Mexico | 0018 665 203 144 |
| Monaco | 8009 3519 |
| Netherlands | 0800 023 5091 |
| New Zealand | 0800 448 423 |
| North China | 1080 071 218 19 |
| Norway | 8001 9414 |
| Philippines | 1800 111 011 58 |
| Poland | 0080 012 126 55 |
| Portugal | 8008 120 40 |
| Romania | 0800 895 055 |
| Russia | 8108 002 097 2044 |
| Russia | 8800 115 6818 |
| Singapore | 8001 203 988 |
| Slovakia | 0800 001 418 |
|---|---|
| Slovenia | 0800 801 74 |
| South Africa | 0800 980 759 |
| South China | 1080 012 018 13 |
| South Korea | 0079 844 312 22 |
| Spain | 8000 995 39 |
| Sweden | 0200 890 171 |
| Switzerland | 0800 828 006 |
| Taiwan | 0080 112 6902 |
| Thailand | 0018 004 421 39 |
| Turkey | 0080 014 203 8193 |
| UAE | 8000 357 030 30 |
| USA | 1866 966 9439 |
Joke Comijn, Corporate Communications Manager +32 (0)477 77 29 44 +32 (0)9 243 40 70 [email protected]
Mark Swallow/David Dible Citigate Dewe Rogerson +44 207 282 2948 [email protected]
Beth DelGiacco (US IR) Stern Investor Relations +1 212 362 1200 [email protected]
The contents of this announcement include statements that are, or may be deemed to be, "forwardlooking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx' actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. "Management's Discussion and Analysis of Financial Condition and Results of Operations"
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.